Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation

To assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. We conducted individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers. We analyzed...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics Vol. 20; no. 18; pp. 1291 - 1302
Main Authors: Deininger, Kimberly M, Tran, Jacinda N, Tsunoda, Shirley M, Young, Gordon K, Lee, Yee Ming, Anderson, Heather D, Page Ii, Robert L, Hirsch, Jan D, Aquilante, Christina L
Format: Journal Article
Language:English
Published: England Future Medicine Ltd 01-12-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. We conducted individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers. We analyzed the qualitative data to identify salient themes. The study enrolled 36 patients and 24 providers. Patients lacked an understanding about PGx, but expressed interest in PGx testing. Providers expressed willingness to use PGx testing, but reported barriers to implementation, such as lack of knowledge, lack of evidence demonstrating clinical utility, and patient healthcare burden. Patient and provider educational efforts, including foundational knowledge, clinical evidence, and applications to patient care beyond just immunosuppression, may be useful to facilitate the use of PGx testing in transplant medicine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2019-0129